Proteomics

Dataset Information

0

Identification of CDK1 phosphorylation of TFCP2L1 from murine embryonic stem cells and bladder cancer cells


ABSTRACT: Molecular programs involved in embryogenesis are frequently upregulated in oncogenic dedifferentiation and metastasis. However, their precise roles and regulatory mechanisms remain elusive. Here, we showed that CDK1 phosphorylation of TFCP2L1, a pluripotency-associated transcription factor, orchestrated pluripotency and cell-cycling in embryonic stem cells (ESCs) and was aberrantly activated in aggressive bladder cancers (BCs). In murine ESCs, the protein interactome and transcription targets of Tfcp2l1 indicated its involvement in cell-cycle regulation. Tfcp2l1 was phosphorylated at Thr177 by Cdk1, which affected ESC cell-cycle progression, pluripotency, and differentiation. LC-MS was used to characterize thr177 phosphorylation in TFCP2L1 protein obtained by IP experiment and kinase assay. The CDK1-TFCP2L1 pathway was activated in human BC cells, stimulating their proliferation, self-renewal, and invasion. Lack of TFCP2L1 phosphorylation impaired the tumorigenic potency of BC cells in a xenograft model. In patients with BC, high co-expression of TFCP2L1 and CDK1 was associated with unfavorable clinical characteristics including tumor grade, lymphovascular and muscularis propria invasion, and distant metastasis and was an independent prognostic factor for cancer specific survival. These findings demonstrate the molecular and clinical significance of CDK1-mediated TFCP2L1 phosphorylation in stem-cell pluripotency and in the tumorigenic stemness features associated with BC progression.

INSTRUMENT(S): LTQ, Q Exactive

ORGANISM(S): Homo Sapiens (human) Mus Musculus (mouse)

TISSUE(S): Cell Culture

SUBMITTER: Kyunggon Kim  

LAB HEAD: Kyunggon Kim

PROVIDER: PXD015635 | Pride | 2019-11-08

REPOSITORIES: Pride

Similar Datasets

2024-01-26 | PXD033180 | Pride
2022-03-15 | PXD020345 | Pride
2017-09-14 | PXD006385 | Pride
2020-08-03 | PXD016293 | Pride
2019-04-09 | PXD011137 | Pride
2023-05-10 | PXD026752 | Pride
2020-03-23 | PXD014356 | Pride
2022-02-15 | PXD014419 | Pride
2024-03-31 | PXD044632 | Pride
2022-05-19 | PXD028307 | Pride